Lymphoma’s Fiercest Foe? New CAR T-Cell Therapy Unleashes Unprecedented Remissions!
- Groundbreaking Results: LYL314 achieves an 88% overall response and a 72% complete response in heavily pretreated large B-cell lymphoma patients.
- Lasting Victory: An incredible 71% of patients achieving complete remission remained cancer-free for six months or longer.
- Future of Treatment: This dual-targeting CAR T-cell therapy, now in pivotal trials, signals a potential new era for lymphoma care.
SOUTH SAN FRANCISCO, Calif. – Hope ignites for patients battling aggressive large B-cell lymphoma (LBCL) as Lyell Immunopharma unveils stunning new data for LYL314. In patients facing their third or later line of treatment – a group often left with few options – this next-generation CAR T-cell therapy demonstrated an astonishing 88% overall response rate and a 72% complete response rate1.
The truly game-changing news lies in the durability: 71% of those who achieved a complete response remained in remission at six months or longer2. LYL314, which uniquely targets both CD19 and CD20 on cancer cells and is enriched with stem-like T-cells for enhanced persistence, is living up to its RMAT and Fast Track designations from the FDA.
"LYL314 has the potential to provide differentiated benefit... in both the complete response rate and durability," stated Dr. Akil Merchant, an investigator on the trial.
With a manageable safety profile suitable for outpatient administration and the pivotal PiNACLE trial (NCT05826535) now enrolling, LYL314 is rapidly advancing, heralding a potential paradigm shift in the fight against this relentless cancer. Lyell also plans a pivotal trial for second-line treatment by early 2026, further expanding hope.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.